Clinical trials: Seizures, Epileptic
Epilepsy; Syndrome, Seizures of Localized Onset
Does Levetiracetam and Carbamazepine Impact the Autonomic Activity of Children With Self-limiting Focal Epilepsy?
The goal of this cross-sectional study is to learn about autonomic cardiac profile changes in children with self-limiting focal epilepsy using levetiracetam and carbamazepine in children with self-limiting focal epilepsy…
- Trial name
- levcbz (NCT06138847)
- Testing
- electroencephalogram
- Where
- Turkey (Türkiye)
- Volunteers
- 119 people
- Sponsor
- İpek Dokurel
Childhood Absence Epilepsy
Why Are Patients With Absence Seizures Absent? A Brain Imaging Study
Our study examines which different brain regions are involved in child absence seizures and how they are related to attention and cognition.
- Trial name
- NCT00393666
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Yale University
Baker Gordon Syndrome, Rare Neurodevelopmental Conditions
Investigating Phenotypic, Epigenetic, and NeuroGenetic Traits in Rare and Ultra-rare Neurodevelopmental Disorders (Project PENGUIN)
Rare genetic neurodevelopmental disorders, such as Syt-1 or Baker Gordon Syndrome (BAGOS) arise from mutations in genes essential for brain development and function, often disrupting neurotransmission and neuronal connectivity.
- Conditions
- Baker Gordon Syndrome, Rare Neurodevelopmental Conditions, Rare Neurogenetic Conditions, Syt-1 Disorder
- Trial name
- NCT07329257
- Testing
- No Intervention: Observational Cohort
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Birth Defects, Pregnancy Complications
UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry)
This is a prospective, observational, exposure-registration and follow-up study of women and their offspring exposed to Keppra® (levetiracetam) and Keppra XR® at the time of conception (i.e., any time from the first day of the…
- Conditions
- Birth Defects, Pregnancy Complications, Epilepsy, Seizures
- Trial name
- NCT00345475
- Where
- United States
- Volunteers
- 516 people
- Sponsor
- UCB Pharma
Seizure
Neurostimulation to the Vagus Nerve for the Reduction in Frequency of Seizures Associated With Epilepsy
The purpose of this study is to see the effects of non-invasive vagal nerve stimulation for the reduction in frequency of seizure associated with epilepsy in subjects 18 or older.
- Trial name
- NCT01910129
- Testing
- gammaCore
- Where
- 2 sites in Australia
- Volunteers
- 13 people
- Sponsor
- ElectroCore INC
Epilepsy
Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated
Vagus Nerve Stimulation (VNS) Therapy has been approved marked for the treatment of epilepsy since 1994. This post-market study is designed to follow the clinical course and outcomes for patients with refractory seizures treated…
- Trial name
- V-COMPAS (NCT01281293)
- Where
- 20 sites in United States, Belgium and 3 more
- Volunteers
- 124 people
- Sponsor
- Cyberonics, Inc.
Epilepsy, Epilepsies, Partial
A Study of the Effectiveness and Safety of Topiramate Monotherapy in Patients With Recently Diagnosed Partial-Onset Seizure
The purposes of this study are (1) to compare the effectiveness of two doses of topiramate and (2) to assess the safety of topiramate alone in the treatment of pediatric and adult patients with recently diagnosed epilepsy…
- Conditions
- Epilepsy, Epilepsies, Partial, Seizures
- Trial name
- NCT00230698
- Testing
- topiramate
- Volunteers
- 451 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Epilepsy
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
The purpose of this study is to determine the safety of perampanel given as adjunctive, long-term treatment in patients with refractory partial onset seizures.
- Trial name
- NCT00368472
- Testing
- Perampanel
- Where
- 47 sites in United States, Australia and 12 more
- Volunteers
- 138 people
- Sponsor
- Eisai Inc.
Epilepsy, Seizures
Genetic Markers of Cardiovascular Disease in Epilepsy
Epilepsy is a common condition which affects over 3 million people in the US. Patients with uncontrolled epilepsy have a lifetime risk of sudden unexpected death (SUDEP) of 35%, which is greatest in those under 40 years of age.
- Conditions
- Epilepsy, Seizures, Syncope, Channelopathy
- Trial name
- NCT02824822
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Mayo Clinic
Epilepsy
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
Methylphenidate (MPH) is a stimulant, FDA-approved for the treatment of attention deficit hyperactivity disorder (ADHD). It is unknown, however, if stimulants would be of benefit for memory and thinking problems due to epilepsy.
- Trial name
- NCT04419272
- Testing
- Methylphenidate
- Where
- 4 sites in United States
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Metastatic Brain Tumor, Primary Brain Tumor
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
The NeuroBlate® System (NBS) is a minimally invasive robotic laser thermotherapy tool that is being manufactured by Monteris Medical.
- Conditions
- Metastatic Brain Tumor, Primary Brain Tumor, Epileptic/Seizure Foci, Movement Disorders
- Trial name
- LAANTERN (NCT02392078)
- Testing
- NeuroBlate System
- Where
- 26 sites in United States
- Volunteers
- 1,153 people
- Sponsor
- Monteris Medical
Drug Resistant Epilepsy
Infrared Photobiomodulation in Humans With Epilepsy
Drug-resistant epilepsy represents roughly 40% of people with epilepsy. It is very challenging to stop seizures in this condition, and the treatment options are limited.
- Trial name
- NCT07145489
- Testing
- photobiomodulation
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Beth Israel Deaconess Medical Center
Epilepsy
Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy
The purpose of this study is to evaluate the pharmacokinetics (PK) of perampanel during the Maintenance Period of the Core Study following oral suspension administration given as an adjunctive therapy in pediatric participants…
- Trial name
- NCT02914314
- Testing
- perampanel
- Where
- 18 sites in United States, Latvia
- Volunteers
- 26 people
- Sponsor
- Eisai Inc.
Dependency on Medications Prescribed for Patient, Types of Seizures and Epileptic Syndromes
A Simulation-based Intervention for Caregivers of Children With Seizures
Caregivers of children with seizures receiving simulation based seizure management teaching in addition to the traditional seizure teaching will report more confidence with seizure management and demonstrate a higher level of…
- Trial name
- NCT01831063
- Testing
- Simulation
- Where
- Canada
- Volunteers
- 61 people
- Sponsor
- University of Calgary
Status Epilepticus
Stiripentol for the Treatment of Refractory Status Epilepticus
The investigators retrospectively analyzed all patients who were admitted to the Department of Neurology at Marburg University Hospital between 2013 and 2023 with a diagnosis of (super)-refractory status epilepticus and who…
- Trial name
- NCT06540378
- Testing
- Stiripentol
- Volunteers
- 25 people
- Sponsor
- University Hospital Marburg
Generalized Epilepsy
Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From Epilepsy
A double-blind trial comparing the efficacy and safety of levetiracetam to carbamazepine used as monotherapy in subjects (≥ 16 years) newly or recently diagnosed as suffering from epilepsy, and experiencing partial or generalized…
- Trial name
- NCT00150735
- Testing
- LEVETIRACETAM
- Volunteers
- 580 people
- Sponsor
- UCB Pharma
Epilepsy, Monotherapy
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
Compare safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR) as monotherapy in newly or recently newly diagnosed subjects with primary safety variables including spontaneous reports of Adverse Events (AEs)…
- Trial name
- NCT01465997
- Testing
- Lacosamide, Carbamazepine-Controlled Release (CBZ-CR)
- Where
- 150 sites in United States, Australia and 27 more
- Volunteers
- 551 people
- Sponsor
- UCB BIOSCIENCES GmbH
Epilepsy
Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset Seizures
Primary: to evaluate the efficacy of phenobarbital in reducing seizure frequency. Secondary: to confirm dose response relationship, to assess the effects on Type I seizures, to assess the safety of phenobarbital to assess the…
- Trial name
- NCT01284556
- Testing
- Phenobarbital
- Where
- 4 sites in United States, Puerto Rico
- Volunteers
- 314 people
- Sponsor
- West-Ward Pharmaceutical
Focal Epilepsy With and Without Secondary Generalization
Real-world Clinical Response to Cenobamate Early add-on in France, Germany and Spain
Aim of the study is to better characterize the clinical profile of adjunctive cenobamate by collecting data from the current standard clinical practice in France, Germany, and Spain, to describe the real-world clinical response…
- Trial name
- NCT06716801
- Testing
- Cenobamate
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Focal Onset Seizure, Focal Onset Epilepsy
A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures
This study will evaluate the safety, pharmacokinetics, and efficacy of three different doses of NBI-921352 versus placebo in adults with focal onset seizures
- Trial name
- NCT05159908
- Testing
- NBI-921352
- Where
- 28 sites in Australia, Belgium and 5 more
- Volunteers
- 101 people
- Sponsor
- Neurocrine Biosciences